Diabetes Mellitus, Type 2
Conditions
Brief summary
The objective of this study is to identify EMR-based clinical covariates and quantify their association with the prescribing of each specific type 2 diabetes (T2DM) medication under investigation. This will include an assessment of how well these covariates are captured through claims data proxies, and their potential to confound comparative research of T2DM medications.
Detailed description
Purpose:
Interventions
non-randomized
Sponsors
Study design
Eligibility
Inclusion criteria
* Dispensing of an oral or non-insulin injected hypoglycemic medication between May 2011 and June 2012 * Diagnosis of type 2 diabetes mellitus * Presence of electronic medical records (for the EMR-based subset)
Exclusion criteria
* Age \<18 at T2DM medication initiation * Missing or ambiguous age or sex information * At least one diagnosis of type 1 diabetes mellitus * Less than 6 months enrolment in the database preceding the date of the first dispensing * Prior use of the index drug
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Missing EMR (Electronic Medical Record) Characteristic: Smoking | Up to 20 months | The missing EMR characteristic smoking defined as current, unknown, versus past/never smoker. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic smoking was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics. |
| Missing EMR Characteristic: Duration of Diabetes | Up to 20 months | The missing EMR characteristic duration of diabetes defined as \>7, 5-6, 3-5, 1-3, \<1 (in years) in duration. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic duration of diabetes was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics. |
| Missing EMR Characteristic: Duration of Diabetes (Continuous) | Up to 20 months | The missing EMR characteristic duration of diabetes defined as starting year/starting age of diabetes. Linear regression models were ran using a prioritized list of claims-based covariates as predictors and the value of select EMR-based clinical characteristics duration of diabetes as continuous outcomes. The estimated value represented is actually prediction accuracy defined by R-squared. |
| Missing EMR Characteristic: BMI (Body Mass Index) | Up to 20 months | The missing EMR characteristic BMI defined as not obese, overweight, obese, severe obesity. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic BMI was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics. |
| Missing EMR Characteristic: BMI (Continuous) | Up to 20 months | The missing EMR characteristic BMI is BMI value. Linear regression models were ran using a prioritized list of claims-based covariates as predictors and the value of select EMR-based clinical characteristics BMI as continuous outcomes. The estimated value represented is actually prediction accuracy defined by R-squared. |
| Missing EMR Characteristic: HbA1c (Hemoglobin A1c (Glycosylated Hemoglobin)) | Up to 20 months | The missing EMR characteristic HbA1c defined as value in 6 months prior to and including index date. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic HbA1c was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics. |
| Missing EMR Characteristic: eGFR (Glomerular Filtration Rate) | Upto 20 months | The missing EMR characteristic eGFR defined as value in 6 months prior to and including index date. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic eGFR was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics. |
| Missing EMR Characteristic: Total Cholesterol | Up to 20 months | The missing EMR characteristic total cholesterol defined as value in 6 months prior to and including index date. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic total cholesterol was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics. |
| Missing EMR Characteristic: Systolic BP (Blood Pressure) | Up to 20 months | The missing EMR characteristic systolic BP defined as value in 6 months prior to and including index date. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic systolic BP was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics. |
| Missing EMR Characteristic: Diastolic BP | Up to 20 months | The missing EMR characteristic diastolic BP defined as value in 6 months prior to and including index date. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic diastolic BP was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics. |
| Binary EMR Characteristic: Neuropathy | Up to 20 months | The missing EMR characteristic neuropathy defined as participants with any note of diabetic neuropathy. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic neuropathy was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics. |
| Binary EMR Characteristic: Nephropathy | Upto 20 months | The missing EMR characteristic nephropathy defined as participants with any note of diabetic nephropathy. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic nephropathy was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics. |
| Binary EMR Characteristic: Retinopathy | Up to 20 months | The missing EMR characteristic retinopathy defined as participants with any note of diabetic retinopathy. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic retinopathy was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics. |
| Binary EMR Characteristic: Pancreatitis | Up to 20 months | The missing EMR characteristic pancreatitis defined as participants with any note of prior pancreatitis. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic pancreatitis was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics. |
Countries
United States
Participant flow
Recruitment details
Existing data cohort design using data from the MarketScan database from May 2011 through December 2012. 492963 potential patients were identified in the database, but after removing patients who violated inclusion and exclusion criteria 166613 patients were actually analysed in the study.
Participants by arm
| Arm | Count |
|---|---|
| Linagliptin 1 Patients had a recorded diagnosis of type 2 diabetes mellitus (T2DM) using an oral and non-insulin injected glucose-lowering medication Linagliptin subjects matched to any other DPP-4 (Dipeptidyl peptidase-4 inhibitors). | 243 |
| Any Other DPP-4 Patients had a recorded diagnosis of type 2 diabetes mellitus (T2DM) using an oral and non-insulin injected glucose-lowering medication DPP-4 (Dipeptidyl peptidase-4 inhibitors). | 3,041 |
| Linagliptin 2 Patients had a recorded diagnosis of type 2 diabetes mellitus (T2DM) using an oral and non-insulin injected glucose-lowering medication Linagliptin subjects matched to pioglitazone. | 205 |
| Pioglitazone Patients had a recorded diagnosis of type 2 diabetes mellitus (T2DM) using an oral and non-insulin injected glucose-lowering medication pioglitazone. | 530 |
| Linagliptin 3 Patients had a recorded diagnosis of type 2 diabetes mellitus (T2DM) using an oral and non-insulin injected glucose-lowering medication Linagliptin subjects matched to second generation sulfonylurea. | 150 |
| Second Generation Sulfonylurea Patients had a recorded diagnosis of type 2 diabetes mellitus (T2DM) using an oral and non-insulin injected glucose-lowering medication second generation sulfonylurea. | 3,050 |
| Total | 7,219 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Overall Study | Not linked | 5,489 | 61,654 | 4,236 | 13,833 | 3,286 | 70,896 |
Baseline characteristics
| Characteristic | Linagliptin 1 | Any Other DPP-4 | Linagliptin 2 | Pioglitazone | Linagliptin 3 | Second Generation Sulfonylurea | Total |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 56.1 Years STANDARD_DEVIATION 11.6 | 54.8 Years STANDARD_DEVIATION 11.2 | 55.2 Years STANDARD_DEVIATION 11.7 | 54.7 Years STANDARD_DEVIATION 11.1 | 54.7 Years STANDARD_DEVIATION 11.8 | 54.8 Years STANDARD_DEVIATION 11.7 | 54.9 Years STANDARD_DEVIATION 11.5 |
| Gender Female | 118 Participants | 1310 Participants | 101 Participants | 194 Participants | 74 Participants | 1332 Participants | 3129 Participants |
| Gender Male | 125 Participants | 1731 Participants | 104 Participants | 336 Participants | 76 Participants | 1718 Participants | 4090 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | โ / โ |
| other Total, other adverse events | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 |
Outcome results
Binary EMR Characteristic: Nephropathy
The missing EMR characteristic nephropathy defined as participants with any note of diabetic nephropathy. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic nephropathy was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.
Time frame: Upto 20 months
Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Linagliptin 1 | Binary EMR Characteristic: Nephropathy | 5.8 Percentage of participants |
| Any Other DPP-4 | Binary EMR Characteristic: Nephropathy | 3.2 Percentage of participants |
| Linagliptin 2 | Binary EMR Characteristic: Nephropathy | 5.9 Percentage of participants |
| Pioglitazone | Binary EMR Characteristic: Nephropathy | 4.3 Percentage of participants |
| Linagliptin 3 | Binary EMR Characteristic: Nephropathy | 4.7 Percentage of participants |
| Second Generation Sulfonylurea | Binary EMR Characteristic: Nephropathy | 3.0 Percentage of participants |
Binary EMR Characteristic: Neuropathy
The missing EMR characteristic neuropathy defined as participants with any note of diabetic neuropathy. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic neuropathy was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.
Time frame: Up to 20 months
Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Linagliptin 1 | Binary EMR Characteristic: Neuropathy | 9.9 Percentage of participants |
| Any Other DPP-4 | Binary EMR Characteristic: Neuropathy | 10.0 Percentage of participants |
| Linagliptin 2 | Binary EMR Characteristic: Neuropathy | 10.7 Percentage of participants |
| Pioglitazone | Binary EMR Characteristic: Neuropathy | 11.3 Percentage of participants |
| Linagliptin 3 | Binary EMR Characteristic: Neuropathy | 12.0 Percentage of participants |
| Second Generation Sulfonylurea | Binary EMR Characteristic: Neuropathy | 11.0 Percentage of participants |
Binary EMR Characteristic: Pancreatitis
The missing EMR characteristic pancreatitis defined as participants with any note of prior pancreatitis. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic pancreatitis was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.
Time frame: Up to 20 months
Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Linagliptin 1 | Binary EMR Characteristic: Pancreatitis | 0.8 Percentage of participants |
| Any Other DPP-4 | Binary EMR Characteristic: Pancreatitis | 0.5 Percentage of participants |
| Linagliptin 2 | Binary EMR Characteristic: Pancreatitis | 1.0 Percentage of participants |
| Pioglitazone | Binary EMR Characteristic: Pancreatitis | 0.2 Percentage of participants |
| Linagliptin 3 | Binary EMR Characteristic: Pancreatitis | 0.7 Percentage of participants |
| Second Generation Sulfonylurea | Binary EMR Characteristic: Pancreatitis | 0.5 Percentage of participants |
Binary EMR Characteristic: Retinopathy
The missing EMR characteristic retinopathy defined as participants with any note of diabetic retinopathy. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic retinopathy was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.
Time frame: Up to 20 months
Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Linagliptin 1 | Binary EMR Characteristic: Retinopathy | 1.2 Percentage of participants |
| Any Other DPP-4 | Binary EMR Characteristic: Retinopathy | 1.9 Percentage of participants |
| Linagliptin 2 | Binary EMR Characteristic: Retinopathy | 1.0 Percentage of participants |
| Pioglitazone | Binary EMR Characteristic: Retinopathy | 2.8 Percentage of participants |
| Linagliptin 3 | Binary EMR Characteristic: Retinopathy | 1.3 Percentage of participants |
| Second Generation Sulfonylurea | Binary EMR Characteristic: Retinopathy | 1.7 Percentage of participants |
Missing EMR Characteristic: BMI (Body Mass Index)
The missing EMR characteristic BMI defined as not obese, overweight, obese, severe obesity. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic BMI was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.
Time frame: Up to 20 months
Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Linagliptin 1 | Missing EMR Characteristic: BMI (Body Mass Index) | Obese | 35.4 Percentage of participants |
| Linagliptin 1 | Missing EMR Characteristic: BMI (Body Mass Index) | Normal | 2.1 Percentage of participants |
| Linagliptin 1 | Missing EMR Characteristic: BMI (Body Mass Index) | Underweight | 0.4 Percentage of participants |
| Linagliptin 1 | Missing EMR Characteristic: BMI (Body Mass Index) | Severe Obesity | 16.5 Percentage of participants |
| Linagliptin 1 | Missing EMR Characteristic: BMI (Body Mass Index) | Overweight | 11.5 Percentage of participants |
| Any Other DPP-4 | Missing EMR Characteristic: BMI (Body Mass Index) | Normal | 3.9 Percentage of participants |
| Any Other DPP-4 | Missing EMR Characteristic: BMI (Body Mass Index) | Obese | 35.1 Percentage of participants |
| Any Other DPP-4 | Missing EMR Characteristic: BMI (Body Mass Index) | Underweight | 0.1 Percentage of participants |
| Any Other DPP-4 | Missing EMR Characteristic: BMI (Body Mass Index) | Severe Obesity | 15.5 Percentage of participants |
| Any Other DPP-4 | Missing EMR Characteristic: BMI (Body Mass Index) | Overweight | 11.8 Percentage of participants |
| Linagliptin 2 | Missing EMR Characteristic: BMI (Body Mass Index) | Normal | 2.0 Percentage of participants |
| Linagliptin 2 | Missing EMR Characteristic: BMI (Body Mass Index) | Obese | 35.1 Percentage of participants |
| Linagliptin 2 | Missing EMR Characteristic: BMI (Body Mass Index) | Severe Obesity | 16.1 Percentage of participants |
| Linagliptin 2 | Missing EMR Characteristic: BMI (Body Mass Index) | Overweight | 13.7 Percentage of participants |
| Linagliptin 2 | Missing EMR Characteristic: BMI (Body Mass Index) | Underweight | 0.5 Percentage of participants |
| Pioglitazone | Missing EMR Characteristic: BMI (Body Mass Index) | Overweight | 15.5 Percentage of participants |
| Pioglitazone | Missing EMR Characteristic: BMI (Body Mass Index) | Underweight | 0.0 Percentage of participants |
| Pioglitazone | Missing EMR Characteristic: BMI (Body Mass Index) | Normal | 3.4 Percentage of participants |
| Pioglitazone | Missing EMR Characteristic: BMI (Body Mass Index) | Obese | 29.6 Percentage of participants |
| Pioglitazone | Missing EMR Characteristic: BMI (Body Mass Index) | Severe Obesity | 10.9 Percentage of participants |
| Linagliptin 3 | Missing EMR Characteristic: BMI (Body Mass Index) | Obese | 36.0 Percentage of participants |
| Linagliptin 3 | Missing EMR Characteristic: BMI (Body Mass Index) | Underweight | 0.7 Percentage of participants |
| Linagliptin 3 | Missing EMR Characteristic: BMI (Body Mass Index) | Severe Obesity | 16.0 Percentage of participants |
| Linagliptin 3 | Missing EMR Characteristic: BMI (Body Mass Index) | Normal | 2.7 Percentage of participants |
| Linagliptin 3 | Missing EMR Characteristic: BMI (Body Mass Index) | Overweight | 10.7 Percentage of participants |
| Second Generation Sulfonylurea | Missing EMR Characteristic: BMI (Body Mass Index) | Underweight | 0.1 Percentage of participants |
| Second Generation Sulfonylurea | Missing EMR Characteristic: BMI (Body Mass Index) | Obese | 34.2 Percentage of participants |
| Second Generation Sulfonylurea | Missing EMR Characteristic: BMI (Body Mass Index) | Normal | 4.0 Percentage of participants |
| Second Generation Sulfonylurea | Missing EMR Characteristic: BMI (Body Mass Index) | Severe Obesity | 15.4 Percentage of participants |
| Second Generation Sulfonylurea | Missing EMR Characteristic: BMI (Body Mass Index) | Overweight | 14.0 Percentage of participants |
Missing EMR Characteristic: BMI (Continuous)
The missing EMR characteristic BMI is BMI value. Linear regression models were ran using a prioritized list of claims-based covariates as predictors and the value of select EMR-based clinical characteristics BMI as continuous outcomes. The estimated value represented is actually prediction accuracy defined by R-squared.
Time frame: Up to 20 months
Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Linagliptin 1 | Missing EMR Characteristic: BMI (Continuous) | 36.3 Kg/m^2 | Standard Deviation 8.5 |
| Any Other DPP-4 | Missing EMR Characteristic: BMI (Continuous) | 35.5 Kg/m^2 | Standard Deviation 8 |
| Linagliptin 2 | Missing EMR Characteristic: BMI (Continuous) | 36.1 Kg/m^2 | Standard Deviation 8.8 |
| Pioglitazone | Missing EMR Characteristic: BMI (Continuous) | 34.2 Kg/m^2 | Standard Deviation 7 |
| Linagliptin 3 | Missing EMR Characteristic: BMI (Continuous) | 36.6 Kg/m^2 | Standard Deviation 9.2 |
| Second Generation Sulfonylurea | Missing EMR Characteristic: BMI (Continuous) | 35.1 Kg/m^2 | Standard Deviation 7.8 |
Missing EMR Characteristic: Diastolic BP
The missing EMR characteristic diastolic BP defined as value in 6 months prior to and including index date. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic diastolic BP was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.
Time frame: Up to 20 months
Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Linagliptin 1 | Missing EMR Characteristic: Diastolic BP | 79.5 mmHg | Standard Deviation 10.6 |
| Any Other DPP-4 | Missing EMR Characteristic: Diastolic BP | 78.8 mmHg | Standard Deviation 10 |
| Linagliptin 2 | Missing EMR Characteristic: Diastolic BP | 80.0 mmHg | Standard Deviation 10.2 |
| Pioglitazone | Missing EMR Characteristic: Diastolic BP | 79.3 mmHg | Standard Deviation 10.6 |
| Linagliptin 3 | Missing EMR Characteristic: Diastolic BP | 80.0 mmHg | Standard Deviation 10.5 |
| Second Generation Sulfonylurea | Missing EMR Characteristic: Diastolic BP | 79.6 mmHg | Standard Deviation 10.5 |
Missing EMR Characteristic: Duration of Diabetes
The missing EMR characteristic duration of diabetes defined as \>7, 5-6, 3-5, 1-3, \<1 (in years) in duration. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic duration of diabetes was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.
Time frame: Up to 20 months
Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Linagliptin 1 | Missing EMR Characteristic: Duration of Diabetes | 5.00-6.99 years | 4.9 Percentage of participants |
| Linagliptin 1 | Missing EMR Characteristic: Duration of Diabetes | 1.00-2.99 years | 11.5 Percentage of participants |
| Linagliptin 1 | Missing EMR Characteristic: Duration of Diabetes | Less than 1 year | 11.9 Percentage of participants |
| Linagliptin 1 | Missing EMR Characteristic: Duration of Diabetes | 7+ years | 5.3 Percentage of participants |
| Linagliptin 1 | Missing EMR Characteristic: Duration of Diabetes | 3.00-4.99 years | 7.8 Percentage of participants |
| Any Other DPP-4 | Missing EMR Characteristic: Duration of Diabetes | 1.00-2.99 years | 14.2 Percentage of participants |
| Any Other DPP-4 | Missing EMR Characteristic: Duration of Diabetes | 5.00-6.99 years | 5.1 Percentage of participants |
| Any Other DPP-4 | Missing EMR Characteristic: Duration of Diabetes | Less than 1 year | 13.7 Percentage of participants |
| Any Other DPP-4 | Missing EMR Characteristic: Duration of Diabetes | 7+ years | 5.3 Percentage of participants |
| Any Other DPP-4 | Missing EMR Characteristic: Duration of Diabetes | 3.00-4.99 years | 7.8 Percentage of participants |
| Linagliptin 2 | Missing EMR Characteristic: Duration of Diabetes | 1.00-2.99 years | 11.2 Percentage of participants |
| Linagliptin 2 | Missing EMR Characteristic: Duration of Diabetes | 5.00-6.99 years | 3.9 Percentage of participants |
| Linagliptin 2 | Missing EMR Characteristic: Duration of Diabetes | 7+ years | 5.4 Percentage of participants |
| Linagliptin 2 | Missing EMR Characteristic: Duration of Diabetes | 3.00-4.99 years | 7.8 Percentage of participants |
| Linagliptin 2 | Missing EMR Characteristic: Duration of Diabetes | Less than 1 year | 12.7 Percentage of participants |
| Pioglitazone | Missing EMR Characteristic: Duration of Diabetes | 3.00-4.99 years | 8.3 Percentage of participants |
| Pioglitazone | Missing EMR Characteristic: Duration of Diabetes | Less than 1 year | 11.1 Percentage of participants |
| Pioglitazone | Missing EMR Characteristic: Duration of Diabetes | 1.00-2.99 years | 10.0 Percentage of participants |
| Pioglitazone | Missing EMR Characteristic: Duration of Diabetes | 5.00-6.99 years | 5.7 Percentage of participants |
| Pioglitazone | Missing EMR Characteristic: Duration of Diabetes | 7+ years | 5.8 Percentage of participants |
| Linagliptin 3 | Missing EMR Characteristic: Duration of Diabetes | 5.00-6.99 years | 4.0 Percentage of participants |
| Linagliptin 3 | Missing EMR Characteristic: Duration of Diabetes | Less than 1 year | 16.0 Percentage of participants |
| Linagliptin 3 | Missing EMR Characteristic: Duration of Diabetes | 7+ years | 5.3 Percentage of participants |
| Linagliptin 3 | Missing EMR Characteristic: Duration of Diabetes | 1.00-2.99 years | 12.7 Percentage of participants |
| Linagliptin 3 | Missing EMR Characteristic: Duration of Diabetes | 3.00-4.99 years | 7.3 Percentage of participants |
| Second Generation Sulfonylurea | Missing EMR Characteristic: Duration of Diabetes | Less than 1 year | 15.4 Percentage of participants |
| Second Generation Sulfonylurea | Missing EMR Characteristic: Duration of Diabetes | 5.00-6.99 years | 4.8 Percentage of participants |
| Second Generation Sulfonylurea | Missing EMR Characteristic: Duration of Diabetes | 1.00-2.99 years | 13.6 Percentage of participants |
| Second Generation Sulfonylurea | Missing EMR Characteristic: Duration of Diabetes | 7+ years | 4.8 Percentage of participants |
| Second Generation Sulfonylurea | Missing EMR Characteristic: Duration of Diabetes | 3.00-4.99 years | 8.4 Percentage of participants |
Missing EMR Characteristic: Duration of Diabetes (Continuous)
The missing EMR characteristic duration of diabetes defined as starting year/starting age of diabetes. Linear regression models were ran using a prioritized list of claims-based covariates as predictors and the value of select EMR-based clinical characteristics duration of diabetes as continuous outcomes. The estimated value represented is actually prediction accuracy defined by R-squared.
Time frame: Up to 20 months
Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Linagliptin 1 | Missing EMR Characteristic: Duration of Diabetes (Continuous) | 3.5 Months | Standard Deviation 3.7 |
| Any Other DPP-4 | Missing EMR Characteristic: Duration of Diabetes (Continuous) | 3.1 Months | Standard Deviation 3.3 |
| Linagliptin 2 | Missing EMR Characteristic: Duration of Diabetes (Continuous) | 3.4 Months | Standard Deviation 3.7 |
| Pioglitazone | Missing EMR Characteristic: Duration of Diabetes (Continuous) | 3.5 Months | Standard Deviation 3.1 |
| Linagliptin 3 | Missing EMR Characteristic: Duration of Diabetes (Continuous) | 3.0 Months | Standard Deviation 3.4 |
| Second Generation Sulfonylurea | Missing EMR Characteristic: Duration of Diabetes (Continuous) | 2.9 Months | Standard Deviation 3 |
Missing EMR Characteristic: eGFR (Glomerular Filtration Rate)
The missing EMR characteristic eGFR defined as value in 6 months prior to and including index date. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic eGFR was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.
Time frame: Upto 20 months
Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Linagliptin 1 | Missing EMR Characteristic: eGFR (Glomerular Filtration Rate) | 103.8 ml/min per 1.73 m^2 | Standard Deviation 19.2 |
| Any Other DPP-4 | Missing EMR Characteristic: eGFR (Glomerular Filtration Rate) | 107.0 ml/min per 1.73 m^2 | Standard Deviation 18 |
| Linagliptin 2 | Missing EMR Characteristic: eGFR (Glomerular Filtration Rate) | 104.9 ml/min per 1.73 m^2 | Standard Deviation 18.7 |
| Pioglitazone | Missing EMR Characteristic: eGFR (Glomerular Filtration Rate) | 108.7 ml/min per 1.73 m^2 | Standard Deviation 19.3 |
| Linagliptin 3 | Missing EMR Characteristic: eGFR (Glomerular Filtration Rate) | 105.5 ml/min per 1.73 m^2 | Standard Deviation 18.5 |
| Second Generation Sulfonylurea | Missing EMR Characteristic: eGFR (Glomerular Filtration Rate) | 106.8 ml/min per 1.73 m^2 | Standard Deviation 18.7 |
Missing EMR Characteristic: HbA1c (Hemoglobin A1c (Glycosylated Hemoglobin))
The missing EMR characteristic HbA1c defined as value in 6 months prior to and including index date. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic HbA1c was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.
Time frame: Up to 20 months
Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Linagliptin 1 | Missing EMR Characteristic: HbA1c (Hemoglobin A1c (Glycosylated Hemoglobin)) | 8.2 Percentage | Standard Deviation 1.4 |
| Any Other DPP-4 | Missing EMR Characteristic: HbA1c (Hemoglobin A1c (Glycosylated Hemoglobin)) | 8.6 Percentage | Standard Deviation 1.9 |
| Linagliptin 2 | Missing EMR Characteristic: HbA1c (Hemoglobin A1c (Glycosylated Hemoglobin)) | 8.3 Percentage | Standard Deviation 1.4 |
| Pioglitazone | Missing EMR Characteristic: HbA1c (Hemoglobin A1c (Glycosylated Hemoglobin)) | 9.0 Percentage | Standard Deviation 2.2 |
| Linagliptin 3 | Missing EMR Characteristic: HbA1c (Hemoglobin A1c (Glycosylated Hemoglobin)) | 8.0 Percentage | Standard Deviation 1.5 |
| Second Generation Sulfonylurea | Missing EMR Characteristic: HbA1c (Hemoglobin A1c (Glycosylated Hemoglobin)) | 8.8 Percentage | Standard Deviation 2 |
Missing EMR Characteristic: Systolic BP (Blood Pressure)
The missing EMR characteristic systolic BP defined as value in 6 months prior to and including index date. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic systolic BP was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.
Time frame: Up to 20 months
Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Linagliptin 1 | Missing EMR Characteristic: Systolic BP (Blood Pressure) | 130.2 mmHg | Standard Deviation 16.3 |
| Any Other DPP-4 | Missing EMR Characteristic: Systolic BP (Blood Pressure) | 129.7 mmHg | Standard Deviation 15.7 |
| Linagliptin 2 | Missing EMR Characteristic: Systolic BP (Blood Pressure) | 131.0 mmHg | Standard Deviation 16.1 |
| Pioglitazone | Missing EMR Characteristic: Systolic BP (Blood Pressure) | 131.5 mmHg | Standard Deviation 17.2 |
| Linagliptin 3 | Missing EMR Characteristic: Systolic BP (Blood Pressure) | 131.2 mmHg | Standard Deviation 17.3 |
| Second Generation Sulfonylurea | Missing EMR Characteristic: Systolic BP (Blood Pressure) | 131.3 mmHg | Standard Deviation 17 |
Missing EMR Characteristic: Total Cholesterol
The missing EMR characteristic total cholesterol defined as value in 6 months prior to and including index date. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic total cholesterol was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.
Time frame: Up to 20 months
Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Linagliptin 1 | Missing EMR Characteristic: Total Cholesterol | 188.8 mg/dl | Standard Deviation 59.7 |
| Any Other DPP-4 | Missing EMR Characteristic: Total Cholesterol | 177.6 mg/dl | Standard Deviation 47 |
| Linagliptin 2 | Missing EMR Characteristic: Total Cholesterol | 189.7 mg/dl | Standard Deviation 62.9 |
| Pioglitazone | Missing EMR Characteristic: Total Cholesterol | 185.8 mg/dl | Standard Deviation 58.8 |
| Linagliptin 3 | Missing EMR Characteristic: Total Cholesterol | 194.6 mg/dl | Standard Deviation 53.1 |
| Second Generation Sulfonylurea | Missing EMR Characteristic: Total Cholesterol | 185.8 mg/dl | Standard Deviation 50.8 |
Missing EMR (Electronic Medical Record) Characteristic: Smoking
The missing EMR characteristic smoking defined as current, unknown, versus past/never smoker. The associations between claims-based covariates and missingness on EMR characteristics were investigated by estimating a logistic regression model (and multinomial logistic regression, depending on the number of categories for the EMR characteristic) for each EMR characteristic where an indicator for missing the EMR characteristic smoking was the dependent variable and all claims-based covariates were included as independent variables. The estimated value represented is actually prediction accuracy defined by C-statistics.
Time frame: Up to 20 months
Population: All subjects in MarketScan cohort meeting inclusion/exclusion criteria. EMR-linked subset: From the study group we identified patients who have EMR data available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Linagliptin 1 | Missing EMR (Electronic Medical Record) Characteristic: Smoking | Current | 9.1 Percentage of participants |
| Linagliptin 1 | Missing EMR (Electronic Medical Record) Characteristic: Smoking | Past | 12.3 Percentage of participants |
| Linagliptin 1 | Missing EMR (Electronic Medical Record) Characteristic: Smoking | Never | 32.9 Percentage of participants |
| Linagliptin 1 | Missing EMR (Electronic Medical Record) Characteristic: Smoking | Unknown | 5.8 Percentage of participants |
| Any Other DPP-4 | Missing EMR (Electronic Medical Record) Characteristic: Smoking | Never | 35.5 Percentage of participants |
| Any Other DPP-4 | Missing EMR (Electronic Medical Record) Characteristic: Smoking | Past | 12.2 Percentage of participants |
| Any Other DPP-4 | Missing EMR (Electronic Medical Record) Characteristic: Smoking | Current | 7.6 Percentage of participants |
| Any Other DPP-4 | Missing EMR (Electronic Medical Record) Characteristic: Smoking | Unknown | 4.9 Percentage of participants |
| Linagliptin 2 | Missing EMR (Electronic Medical Record) Characteristic: Smoking | Unknown | 6.3 Percentage of participants |
| Linagliptin 2 | Missing EMR (Electronic Medical Record) Characteristic: Smoking | Never | 32.7 Percentage of participants |
| Linagliptin 2 | Missing EMR (Electronic Medical Record) Characteristic: Smoking | Past | 12.2 Percentage of participants |
| Linagliptin 2 | Missing EMR (Electronic Medical Record) Characteristic: Smoking | Current | 10.7 Percentage of participants |
| Pioglitazone | Missing EMR (Electronic Medical Record) Characteristic: Smoking | Current | 7.9 Percentage of participants |
| Pioglitazone | Missing EMR (Electronic Medical Record) Characteristic: Smoking | Unknown | 5.1 Percentage of participants |
| Pioglitazone | Missing EMR (Electronic Medical Record) Characteristic: Smoking | Past | 10.2 Percentage of participants |
| Pioglitazone | Missing EMR (Electronic Medical Record) Characteristic: Smoking | Never | 30.8 Percentage of participants |
| Linagliptin 3 | Missing EMR (Electronic Medical Record) Characteristic: Smoking | Never | 34.7 Percentage of participants |
| Linagliptin 3 | Missing EMR (Electronic Medical Record) Characteristic: Smoking | Unknown | 6.0 Percentage of participants |
| Linagliptin 3 | Missing EMR (Electronic Medical Record) Characteristic: Smoking | Past | 10.7 Percentage of participants |
| Linagliptin 3 | Missing EMR (Electronic Medical Record) Characteristic: Smoking | Current | 11.3 Percentage of participants |
| Second Generation Sulfonylurea | Missing EMR (Electronic Medical Record) Characteristic: Smoking | Past | 10.9 Percentage of participants |
| Second Generation Sulfonylurea | Missing EMR (Electronic Medical Record) Characteristic: Smoking | Never | 33.3 Percentage of participants |
| Second Generation Sulfonylurea | Missing EMR (Electronic Medical Record) Characteristic: Smoking | Unknown | 6.5 Percentage of participants |
| Second Generation Sulfonylurea | Missing EMR (Electronic Medical Record) Characteristic: Smoking | Current | 9.4 Percentage of participants |